Related to ProMetic Earns $1M First Milestone

• PTC Therapeutics Receives $1.6M from FDA Orphan Drug Grant
  
• GSK Pays Amicus $30M Up Front for Phase III Fabry Disease Drug
  
• EMA Road Map Aims to Stimulate Drug Development for Unmet Medical Needs and Rare and Neglected Diseases
  
• Sanofi-Aventis and Genzyme Finally Agree to $20.1B plus CVR Acquisition Deal
  
• Aerie Raises $30M to Progress Glaucoma Drug into Phase III
  
• Enobia Chooses Lonza for Commercial-Scale Manufacture of Its Enzyme-Replacement Therapy
  
• Synageva Raises $25M Through Private Placement with Existing Investors
  
• Allergy Therapeutics Firm Anergis Raises $20M in Series A Fundraising
  
• Pfizer to Attack Lysosomal Storage Diseases with Zacharon’s Small Molecule Approach
  
• Pfizer’s TTR-FAP Candidate Slows Disease Progression in Pivotal Trial Extension
  
• ViroPharma Licenses Halozyme’s Hyaluronidase for $9M to Develop Subcutaneous Cinryze
  
• FDA Clears Expanded Access Program for Edison’s Mitochondrial Diseases Candidate
  
• Ambit Scores $30M to Advance Kinase Inhibitor Pipeline
  
• GSK, Lilly Venture Funds Join in Nimbus Discovery’s $24M Series A Financing Round
  
• ViroPharma Will Buy DuoCort for $33.6M Up Front if EU-Filed Hydrocortisone Drug Is Approved
  
• EC Sanction of DuoCort’s Plenadren Triggers ViroPharma’s $33M Acquisition of Swedish Firm
  
• Pfizer’s Vyndaqel Gets EC Approval for Transthyretin Familial Amyloid Polyneuropathy Therapy
  
• ViroPharma Pays Meritage Initial $7.5M for Option to Acquire Firm for EoE Drug
  
• Alexion Pays $610M to Buy Enobia for Hypophosphatasia ERT Candidate
  
• Biopharma Investment Grows During Q4 but VCs Fund Fewer Early Deals